Tuesday 13th December 2016
Wednesday 28th September 2016
Nintedanib Receives Orphan Drug Designation for Systemic Sclerosis
The FDA has granted Orphan Drug Designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis (SSc), also known as scleroderma, including associated interstitial lung disease (SSc-ILD). - See more at: http://www.pharmacytimes.com/product-news/nintedanib-receives-orphan-drug-designation-for-systemic-sclerosis#sthash.5ACj39Ga.dpuf
Monday 13th June 2016
The BSR/BHPR Guideline for Scleroderma - what does it mean for patients?
Over the past 2 years an intensive amount of work has been undertaken to develop the first national UK guideline for treatment of scleroderma. This has been a group effort performed on behalf of the BSR (British Society of Rheumatology) and BHPR (British Health Professionals in Rheumatology) to develop an expert driven evidence based series of recommendations for the management of scleroderma.
Friday 10th June 2016
SHARE initiative improved paediatric rheumatology care
The European Union funded SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) initiative, which was undertaken in 2012-2015 to improve and release guidelines for diagnosis and management of rheumatic conditions, is facilitating improvement and uniformity of care for paediatric rheumatology patients throughout Europe.
Saturday 4th June 2016
Childhood Scleroderma: Staying One Step Ahead of a Rare Disease
Clare Pain, MD, consultant pediatric rheumatologist in the Department of Rheumatology at Alder Hey Children's NHS Foundation Trust in Liverpool, England, further explained the disease.
Thursday 26th May 2016
Cytori Fully Enrols Pivotal US Phase III Scleroderma Trial
Cytori Therapeutics Inc. announces that its US FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrolment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.
Monday 23rd May 2016
Report: British Society for Rheumatology (BSR) Conference 2016
On Tuesday 26th through to the 28th of April, The British Society for Rheumatology held their annual conference, with this year’s venue being in Glasgow.
Friday 13th May 2016
Phase 2 Trial Suggests Tocilizumab May Be of Benefit to Systemic Sclerosis Patients
Wednesday 11th May 2016
Protein, Netrin-1, Seen to Promote Lung Fibrosis in Early Scleroderma Study
Friday 6th May 2016
Cumberland Readying a Phase 2 Trial of Oral Drug, Ifetroban, to Treat Scleroderma
Cumberland Pharmaceuticals, Inc., recently announced the addition to its drug pipeline of Vasculan (ifetroban), an oral capsule that soon will enter clinical testing as a treatment of systemic sclerosis (SSc), or scleroderma.